Personalis, Inc. (NASDAQ:PSNL) Holdings Cut by Cubist Systematic Strategies LLC

Cubist Systematic Strategies LLC lowered its holdings in shares of Personalis, Inc. (NASDAQ:PSNL) by 83.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 25,686 shares of the company’s stock after selling 131,553 shares during the quarter. Cubist Systematic Strategies LLC’s holdings in Personalis were worth $148,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of PSNL. JPMorgan Chase & Co. raised its holdings in shares of Personalis by 2,827.0% during the 4th quarter. JPMorgan Chase & Co. now owns 5,854 shares of the company’s stock valued at $34,000 after purchasing an additional 5,654 shares in the last quarter. Olympiad Research LP bought a new position in shares of Personalis during the 4th quarter valued at $59,000. Alpine Global Management LLC bought a new position in shares of Personalis during the 4th quarter valued at $60,000. SG Americas Securities LLC bought a new position in shares of Personalis during the 4th quarter valued at $63,000. Finally, Raymond James Financial Inc. bought a new position in shares of Personalis during the 4th quarter valued at $64,000. Institutional investors own 61.91% of the company’s stock.

Personalis Price Performance

NASDAQ PSNL opened at $4.95 on Monday. The firm has a market capitalization of $437.21 million, a price-to-earnings ratio of -2.95 and a beta of 1.83. The company’s fifty day moving average is $3.76 and its two-hundred day moving average is $4.45. Personalis, Inc. has a 52-week low of $1.14 and a 52-week high of $7.20.

Personalis (NASDAQ:PSNL) last posted its quarterly earnings results on Tuesday, May 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.05. The company had revenue of $20.61 million for the quarter, compared to analyst estimates of $17.41 million. Personalis had a negative net margin of 104.52% and a negative return on equity of 66.07%. As a group, sell-side analysts expect that Personalis, Inc. will post -1.4 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on PSNL. Craig Hallum assumed coverage on shares of Personalis in a report on Monday, March 17th. They set a “buy” rating and a $8.00 price target on the stock. Guggenheim assumed coverage on shares of Personalis in a research note on Thursday. They issued a “buy” rating and a $6.00 target price on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $7.00 target price on shares of Personalis in a research note on Thursday, April 10th. Finally, HC Wainwright raised their target price on shares of Personalis from $8.00 to $9.00 and gave the company a “buy” rating in a research note on Wednesday, May 7th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $7.67.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.